Diseases & Longevity · File 26

Clinical anxiety. The most prevalent mental disorder — and bidirectional comorbidity of the entire cluster.

Anxiety disorders affect approximately 301 million adults globally — the most prevalent mental disorder. Beyond quality-of-life impact, they are bidirectional comorbidity with depression, OSA, cardiometabolic cluster, poorly controlled asthma, and major chronic diseases. Serious longevity medicine doesn't treat them as an annex — addresses them as an integral piece of the systemic cluster.

Why clinical anxiety is a systemic longevity axis

Clinical anxiety is not "normal stress". Anxiety disorders — GAD, social phobia, panic, agoraphobia — are clinical conditions with diagnostic criteria (DSM-5, ICD-11), effective treatment, and measurable biology: HPA axis hyperactivation (cortisol), autonomic dysfunction (reduced HRV), inflammaging (elevated hsCRP), sleep alteration, and identifiable neurobiological substrate.

Its systemic impact is real: clinical anxiety increases cardiovascular event risk (Roest 2010, JACC), worsens asthma control, worsens OSA, amplifies metabolic cluster, worsens adherence to chronic treatments, and increases mortality. The Lancet Commission 2024 includes depression (frequently comorbid with anxiety) as one of 14 modifiable factors for dementia prevention. Treating it seriously is real longevity medicine — not an annex.

Clinical anxiety is not normal stress. It's systemic illness with measurable biology — and bidirectional comorbidity of the cardiometabolic cluster.
Adults over lifetime

The global weight, in numbers

Data come from GBD, WHO, ESEMeD, and comorbidity meta-analyses — the picture confirms the systemic magnitude of the problem.

  • Global prevalence

    ~301M · WHO 2022

    Approximately 301 million adults live with anxiety disorders globally — the most prevalent mental disorder. Approximately 1 in 4 adults experiences clinical anxiety disorder at some point in life.
    — GBD 2019; WHO 2022

  • Depression comorbidity

    ~50% coexisten

    Approximately 50% of clinical anxiety patients have coexistent clinical depression. Comorbidity amplifies severity, chronicity risk, and treatment resistance — requires joint approach.
    — Kessler et al., Arch Gen Psychiatry 2003

  • Cardiovascular events

    Riesgo independiente

    Multiple cohorts (Roest 2010 JACC) show clinical anxiety predicts cardiovascular events (MI, stroke) independently — mechanism is dysautonomia, inflammaging, worse adherence to preventive treatments.
    — Roest et al., JACC 2010

  • Effective treatment

    TCC, SSRI/SNRI, mindfulness

    Cognitive-behavioral therapy (CBT), SSRI/SNRI, mindfulness, and aerobic exercise have well-established efficacy in anxiety disorders. CBT + pharmacotherapy combination surpasses either alone in moderate-severe cases.
    — Bandelow et al., Eur Neuropsychopharmacol 2015

Chap. 03 · Mental health amplifier

The amplified comorbidity cluster

Clinical anxiety amplifies the systemic cluster — and is in turn amplified by poorly managed chronic diseases. Its treatment improves measurable biological axes.

  • Bidirectional depression

    ~50% comorbilidad

    Approximately half of anxiety patients have coexistent clinical depression — comorbidity amplifies severity and worsens prognosis. Treating both simultaneously is modern standard.
    — Kessler Arch Gen Psychiatry 2003

  • OSA and sleep

    Bidireccional

    Chronic insomnia, fragmented sleep, and OSA significantly worsen anxiety — and anxiety worsens sleep. CPAP in confirmed OSA and structured insomnia management improve both. Polysomnography when suspected.
    — Hertenstein et al., Sleep Med Rev 2019

  • Asthma and respiratory

    Empeoramiento percibido

    Clinical anxiety worsens perceived asthma control, increases SABA use, and worsens quality of life — independently of objective control. Addressing anxiety is integral to respiratory management in comorbid patients.
    — Lavoie et al., Respir Med 2006

  • CV events and adherence

    Riesgo aumentado

    Clinical anxiety is associated with worse adherence to preventive cardiovascular treatments (statins, antihypertensives), higher emergency use for somatic symptoms, and higher CV event risk. Its management is indirect CV prevention.
    — Roest JACC 2010

What we don't offer — and what we do

Wellness Care does not replace the psychiatrist or psychotherapist. SSRI / SNRI / benzodiazepine prescription, formal cognitive-behavioral therapy, and management of established anxiety disorders with severe psychiatric comorbidity are exclusively specialized mental health competence. What we do: integrated cluster evaluation (anxiety + cardiometabolic + sleep + inflammaging), identification of modifiable causes, and coordination with psychiatry and psychology when clinically indicated.

We evaluate patients with: clinical anxiety affecting longevity trajectory (CV comorbidity, poorly controlled asthma, cardiometabolic cluster, altered sleep), prolonged benzodiazepine use requiring optimization (preferably in coordination with psychiatrist), identifiable modifiable factors (hyperthyroidism, nutritional deficits, untreated OSA, metabolic cluster, caffeine / alcohol abuse), and post-treatment longevity trajectory. Coordination with mental health always when indicated.

Mental health is not annex — it's a measurable systemic axis. Ignoring it in a longevity protocol is ignoring half the patient.
How we measure it

How anxiety is evaluated
at Wellness Care

GAD-7 + measurable biology (cortisol, thyroid, inflammaging, sleep) + cluster comorbidities + coordination with mental health when indicated. That integration changes real trajectory.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the modern conversation — global prevalence, CV comorbidity, effective treatment, depression comorbidity.

«Los trastornos de ansiedad son el trastorno mental más prevalente a nivel global, con ~301 millones de adultos afectados.»
WHO · 2022
WHO Mental Health Report 2022
Prevalencia global
«La ansiedad clínica es predictor independiente de eventos cardiovasculares mayores — el mecanismo combina disautonomía, inflammaging y peor adherencia.»
JACC · 2010
Roest et al., JACC 2010
Ansiedad y eventos CV
«La combinación TCC + SSRI/SNRI supera la eficacia de cualquiera de los dos por sí solo en trastornos de ansiedad moderados-severos.»
Eur Neuropsychopharmacol · 2015
Bandelow et al., 2015
Eficacia terapéutica

Frequently asked questions about clinical anxiety

The most recurrent questions about clinical anxiety — screening, treatment, systemic comorbidities, and why longevity medicine integrates it as an axis, not annex.

01

What's the difference between normal anxiety and anxiety disorder?

Normal anxiety:

· Adaptive response
· Proportional to stressor
· Transient

Clinical anxiety disorder:

· Disproportionate intensity to stressor
· Persistence (>6 months in GAD)
· Significant functional impact — work, social, family
· Somatic symptoms — palpitations, dyspnea, sustained muscle tension, altered sleep

Formal diagnostic criteria (DSM-5, ICD-11) are applied by psychiatry.

GAD-7 is a useful screening tool in primary care.

02

What medical causes can simulate anxiety?

Multiple — ruling them out is priority before labeling the picture as exclusively psychiatric:

· Hyperthyroidism
· Hypoglycemia
· Pheochromocytoma
· Vitamin B12 deficiency
· Anemia
· OSA
· Arrhythmias — AF, supraventricular tachycardia
· Drug side effects — bronchodilators, corticosteroids, stimulants
· Caffeine abuse
· Alcohol abuse or withdrawal
· Benzodiazepine withdrawal
· Stimulant drugs

Structured medical evaluation is indispensable.

03

What treatments have best evidence?

Interventions with most evidence:

· Cognitive-behavioral therapy (CBT) — first line in many cases, particularly GAD and social phobia
· SSRI / SNRI — sertraline, escitalopram, venlafaxine, duloxetine
· Regular aerobic exercise
· Mindfulness and evidence-based practices
· Sleep management
· Addressing medical comorbidities

CBT + pharmacotherapy combination surpasses either alone in moderate-severe cases.

Benzodiazepines have limited role due to dependence risk — use only under psychiatric prescription.

04

When to refer to mental health?

Refer to psychiatry / psychology when:

· Moderate-severe clinical anxiety
· Significant psychiatric comorbidity — severe depression, substance use disorder, bipolar disorder, suspected PTSD
· Self-harm or suicidal ideation
· Recurrent panic attacks
· Disabling agoraphobia
· Lack of response to primary care management
· Requirement for structured formal psychotherapy
· Need for specialized pharmacological prescription

Referral is not failure of management — it's modern standard of integrated care.

05

When should I consult?

An integrated assessment is worthwhile if you have:

· Persistent anxiety with functional impact (work, social, family)
· Anxiety coexistent with chronic illness (poorly controlled asthma, previous CV events, cardiometabolic cluster, OSA)
· Prolonged benzodiazepine use you want to optimize
· Somatic symptoms without clear organic explanation (palpitations, dyspnea, sustained tension)
· Want to understand the measurable biological axes (cortisol, inflammaging, sleep) sustaining the trajectory

The assessment complements mental health — we always refer when indicated.

Mental health as axis, not annex

Clinical anxiety is not normal stress — it's systemic illness with measurable biology, and bidirectional comorbidity of the cluster.

Rule out medical causes, measure biological axes (cortisol, thyroid, inflammaging, sleep), integrate cluster comorbidities, and coordinate with psychiatry / psychology when indicated — that integration changes real trajectory.

Persistent anxiety affecting your life?

Book a comprehensive assessment including the mental axis

We evaluate clinical history, GAD-7, systemic inflammatory profile (hsCRP), hormonal profile (cortisol, thyroid), micronutrients, sleep, and cluster comorbidities. If clinical anxiety requires pharmacological management or formal psychotherapy, we coordinate with psychiatry / psychology. We don't replace them — we complement.

Book comprehensive assessment with mental health